JP2023502276A - Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法 - Google Patents

Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法 Download PDF

Info

Publication number
JP2023502276A
JP2023502276A JP2022529715A JP2022529715A JP2023502276A JP 2023502276 A JP2023502276 A JP 2023502276A JP 2022529715 A JP2022529715 A JP 2022529715A JP 2022529715 A JP2022529715 A JP 2022529715A JP 2023502276 A JP2023502276 A JP 2023502276A
Authority
JP
Japan
Prior art keywords
vaccine
formula
reactor
charged
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502276A5 (OSRAM
Inventor
ワイアンド，マイケル
エフ スウィス，ジェラルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alopexx Inc
Original Assignee
Alopexx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alopexx Inc filed Critical Alopexx Inc
Publication of JP2023502276A publication Critical patent/JP2023502276A/ja
Publication of JP2023502276A5 publication Critical patent/JP2023502276A5/ja
Priority to JP2025178576A priority Critical patent/JP2026016535A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022529715A 2019-11-22 2020-11-20 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法 Pending JP2023502276A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025178576A JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962939331P 2019-11-22 2019-11-22
US62/939,331 2019-11-22
US202062994130P 2020-03-24 2020-03-24
US62/994,130 2020-03-24
PCT/US2020/061594 WO2021102320A1 (en) 2019-11-22 2020-11-20 Methods for providing continuous therapy against pnag comprising microbes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025178576A Division JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Publications (2)

Publication Number Publication Date
JP2023502276A true JP2023502276A (ja) 2023-01-23
JP2023502276A5 JP2023502276A5 (OSRAM) 2023-11-29

Family

ID=75980043

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022529715A Pending JP2023502276A (ja) 2019-11-22 2020-11-20 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法
JP2025178576A Pending JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025178576A Pending JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Country Status (11)

Country Link
US (1) US20230053458A1 (OSRAM)
EP (1) EP4061411A4 (OSRAM)
JP (2) JP2023502276A (OSRAM)
KR (1) KR20220107001A (OSRAM)
CN (1) CN114845731A (OSRAM)
AU (1) AU2020386971A1 (OSRAM)
BR (1) BR112022009924A2 (OSRAM)
CA (1) CA3162238A1 (OSRAM)
IL (1) IL293091A (OSRAM)
WO (1) WO2021102320A1 (OSRAM)
ZA (1) ZA202205546B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220079534A (ko) * 2019-08-27 2022-06-13 알로펙스, 인크. 항미생물 백신 조성물
US11173199B2 (en) * 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
US20260015434A1 (en) * 2022-03-11 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Antibody materials and methods targeting microbial polysaccharides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501317A (ja) * 2004-04-21 2008-01-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ポリ−Ｎ−アセチルグルコサミン（ＰＮＡＧ／ｄＰＮＡＧ）結合ペプチドおよびその使用方法
WO2011133227A2 (en) * 2010-04-23 2011-10-27 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphyloccocus vaccine
JP2011528710A (ja) * 2008-07-21 2011-11-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド β−１，６−グルコサミンオリゴ糖を合成するための方法および組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145626A1 (en) * 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
EP2847216A1 (en) * 2012-05-07 2015-03-18 Sanofi Methods for preventing biofilm formation
JP2015517496A (ja) * 2012-05-07 2015-06-22 サノフイ バイオフィルム形成を防止する方法
RU2019101166A (ru) * 2012-05-30 2020-03-02 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Композиции полисахаридов и способы применения
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501317A (ja) * 2004-04-21 2008-01-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ポリ−Ｎ−アセチルグルコサミン（ＰＮＡＧ／ｄＰＮＡＧ）結合ペプチドおよびその使用方法
JP2011528710A (ja) * 2008-07-21 2011-11-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド β−１，６−グルコサミンオリゴ糖を合成するための方法および組成物
WO2011133227A2 (en) * 2010-04-23 2011-10-27 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphyloccocus vaccine

Also Published As

Publication number Publication date
WO2021102320A1 (en) 2021-05-27
US20230053458A1 (en) 2023-02-23
JP2026016535A (ja) 2026-02-03
EP4061411A1 (en) 2022-09-28
IL293091A (en) 2022-07-01
EP4061411A4 (en) 2023-11-29
KR20220107001A (ko) 2022-08-01
BR112022009924A2 (pt) 2022-08-09
CN114845731A (zh) 2022-08-02
ZA202205546B (en) 2023-05-31
AU2020386971A1 (en) 2022-06-09
CA3162238A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
JP2026016535A (ja) Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法
CN102159540B (zh) 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
AU750701B2 (en) Alpha-O-linked glycoconjugates, methods of preparation and uses thereof
KR102713536B1 (ko) 클렙시엘라 뉴모니아에 대한 백신
US20210244808A1 (en) Methods for inhibiting biofilm formation
JP2026021461A (ja) 低汚染抗菌ワクチン
KR20220079534A (ko) 항미생물 백신 조성물
JP2022516837A (ja) Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する安定なワクチン
HK40077830A (en) Methods for providing continuous therapy against pnag comprising microbes
HK40078447A (en) Low contaminant antimicrobial vaccines
HK40076154A (en) Antimicrobial vaccine compositions
HK1157750A (en) Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
HK1157750B (en) Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250624